EUVIMEDEUVIMED entdecken
Crossref

Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program

Anselmo Abdo-Cuza, Roberto Castellanos-Gutiérrez, Janete Treto-Ramirez, Sandra Arencibia-Larin, Thalía Gómez-Pariente, Tania González-Fernández, Julio C. Hernández-Perera, Katia Arocha-Stalella, Niurka Verdecia-Gorrita, Lisy Vento-Buigues, Yanet Cordero-Vasallo, Yusmel Rivero-Yi und 12 weitere

Journal of Renal Endocrinology · 2020

DOI: 10.34172/jre.2021.05 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Renal Endocrinology, 2020. Verfasst von Anselmo Abdo-Cuza und 23 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients diagnosed with end-stage chronic kidney disease on a hemodialysis program (HDP) represent a risk group for COVID-19. Scientific societies have developed guidelines for the prevention of contagion, but there is no prophylactic medicine in them.

Objectives

To describe the safety and efficacy of recombinant intranasal human Interferon alfa 2b as prophylaxis for COVID-19 in patients in an HDP. Patients and Methods: Intervention description through the monitoring of 15 patients in outpatient HDP. Prior to the administration of the drug, clinical, radiological evaluation and hematology and blood chemistry studies were performed. Daily contact was made with each study patient in person or by telephone, asking about the occurrence of adverse events or symptoms of disease.

Results

In 47% of the patients, there was leukopenia, lymphopenia in 67% and anemia and thrombocytopenia in 33% respectively, prior to the use of the drug. There was no clinical suspicion of COVID-19 in any of them. Adverse events occurred in 3 patients (20%), all were mild and non-severe. All patients were negative for SARS-CoV-2 real-time polymerase chain reaction (rtPCR) and antibody studies 45 days after the study started. Conclusion: the use of intranasal recombinant human interferon alfa 2b as prophylaxis of COVID-19 in patients in a HDP at a dose of 1 MIU daily for ten days, as part of a prevention protocol, has an adequate safety profile. None of the patients in the series was infected with SARS-CoV-2 during the surveillance period.

Zitieren

APA

Abdo-Cuza, A., Castellanos-Gutiérrez, R., Treto-Ramirez, J., Arencibia-Larin, S., Gómez-Pariente, T., González-Fernández, T., Hernández-Perera, J. C., Arocha-Stalella, K., Verdecia-Gorrita, N., Vento-Buigues, L., Cordero-Vasallo, Y., Rivero-Yi, Y., González-Dias, O., Nodarse-Cuni, H., Machado-Martínez, R., Blanco-González, M. A., Valdivia-Arencibia, J., Mendez-Felipe, D., Delgado-Almora, E., …, & Bejerano-Gil, N. (2020). Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. Journal of Renal Endocrinology. https://doi.org/10.34172/jre.2021.05

Vancouver

Abdo-Cuza A, Castellanos-Gutiérrez R, Treto-Ramirez J, Arencibia-Larin S, Gómez-Pariente T, González-Fernández T, et al. Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. Journal of Renal Endocrinology. 2020. doi:10.34172/jre.2021.05

BibTeX
@article{AbdoCuza2020,
  author = {Abdo-Cuza, Anselmo and Castellanos-Gutiérrez, Roberto and Treto-Ramirez, Janete and Arencibia-Larin, Sandra and Gómez-Pariente, Thalía and González-Fernández, Tania and Hernández-Perera, Julio C. and Arocha-Stalella, Katia and Verdecia-Gorrita, Niurka and Vento-Buigues, Lisy and Cordero-Vasallo, Yanet and Rivero-Yi, Yusmel and González-Dias, Odalys and Nodarse-Cuni, Hugo and Machado-Martínez, Rafael and Blanco-González, Miguel A. and Valdivia-Arencibia, Julio and Mendez-Felipe, Daymiris and Delgado-Almora, Ernesto and Gutiérrez-Gutiérrez, Carlos and Suárez-López, Juliette and Leiva-Torres, Jorge L. and Rodríguez-Sotolongo, Alicia and Bejerano-Gil, Nilda},
  title = {Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program},
  journal = {Journal of Renal Endocrinology},
  year = {2020},
  doi = {10.34172/jre.2021.05}
}
Kostenlos starten →